These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 679894)

  • 1. Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine.
    Wada JA; Troupin AS; Friel P; Remick R; Leal K; Pearmain J
    Epilepsia; 1978 Jun; 19(3):251-5. PubMed ID: 679894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fallacious results from measuring salivary carbamazepine concentrations.
    Dickinson RG; Hooper WD; King AR; Eadie MJ
    Ther Drug Monit; 1985; 7(1):41-5. PubMed ID: 3992621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palatability and relative bioavailability of an extemporaneous carbamazepine oral suspension.
    Bloomer D; Dupuis LL; MacGregor D; Soldin SJ
    Clin Pharm; 1987 Aug; 6(8):646-9. PubMed ID: 3691011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients.
    Morselli PL; Monaco F; Gerna M; Recchia M; Riccio A
    Epilepsia; 1975 Dec; 16(5):759-64. PubMed ID: 1222752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability of rectally administered carbamazepine suspension in humans.
    Graves NM; Kriel RL; Jones-Saete C; Cloyd JC
    Epilepsia; 1985; 26(5):429-33. PubMed ID: 4043011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions.
    Brewster ME; Anderson WR; Meinsma D; Moreno D; Webb AI; Pablo L; Estes KS; Derendorf H; Bodor N; Sawchuk R; Cheung B; Pop E
    J Pharm Sci; 1997 Mar; 86(3):335-9. PubMed ID: 9050802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bioavailability of carbamazepine.
    Cotter LM; Smith G; Hooper WD; Tyrer JH; Eadie MJ
    Proc Aust Assoc Neurol; 1975; 12():123-8. PubMed ID: 1215378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of rectally administered carbamazepine suspension in dogs.
    Graves NM; Kriel RL; Cloyd JC
    Epilepsia; 1983 Oct; 24(5):604-8. PubMed ID: 6617591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment.
    Cawello W; Bökens H; Nickel B; Andreas JO; Halabi A
    Epilepsia; 2013 Jan; 54(1):81-8. PubMed ID: 23148731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative bioavailability of carbamazepine in 100 mg and 200 mg tablets.
    Smith GA; Hooper WD; Tyrer JH; Eadie MJ; Werth B
    Clin Exp Pharmacol Physiol; 1979; 6(1):37-40. PubMed ID: 761426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of carbamazepine in normal man.
    Levy RH; Pitlick WH; Troupin AS; Green JR; Neal JM
    Clin Pharmacol Ther; 1975 Jun; 17(6):657-68. PubMed ID: 1139857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and central side effects of different carbamazepine tablets.
    Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):226-32. PubMed ID: 3997307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative bioavailability of two carbamazepine tablets.
    Glende M; Hüller H; Mai I; Migulla H; Prümke J; Schumann G
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):631-3. PubMed ID: 6668101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioavailability of two commercial preparations of carbamazepine tablets.
    Anttila M; Kahela P; Panelius M; Yrjänä T; Tikkanen R; Aaltonen R
    Eur J Clin Pharmacol; 1979 Jul; 15(6):421-5. PubMed ID: 583039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of sulfadiazine solutions, suspensions, and tablets in humans.
    Meyer MC; Straughn AB; Ramachander G; Cavagnol JC; Biola Mabadeje AF
    J Pharm Sci; 1978 Dec; 67(12):1659-61. PubMed ID: 581498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
    Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
    Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of carbamazepine in plasma and saliva of man.
    Pynnönen S
    Acta Pharmacol Toxicol (Copenh); 1977 Nov; 41(5):465-71. PubMed ID: 579557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the bioavailability of two carbamazepine preparations (200 and 400 mg tablets).
    Monaco F; Porcella V
    J Int Med Res; 1984; 12(2):108-13. PubMed ID: 6724125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of four different pharmaceutical preparations of carbamazepine.
    Pynnönen S; Mäntylä R; Iisalo E
    Acta Pharmacol Toxicol (Copenh); 1978 Oct; 43(4):306-10. PubMed ID: 362821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.